Zai Lab LTD

Zai Lab announced its second quarter 2026 financial results, highlighting total revenues of $106.3 million and significant progress in its oncology and immunology pipelines, with key clinical and regulatory milestones anticipated.

Zai Lab Limited announced that President and Chief Operating Officer Josh Smiley will step down from his roles effective May 18, 2026.

Zai Lab reported Q1 2026 results with a 6% revenue decrease year-over-year, primarily due to ZEJULA sales, while highlighting advancements in its oncology and immunology pipeline.

Zai Lab Limited announced robust financial results for the fourth quarter and full year 2025, driven by product revenue growth and significant pipeline advancements, while reducing net losses.

Zai Lab Limited reported a 14% year-over-year revenue increase to $116.1 million in Q3 2025, alongside a 28% improvement in operating loss, and revised full-year revenue guidance to at least $460 million.

Zai Lab Limited has secured a revolving credit facility of up to RMB300 million (approximately $42.1 million) for its China operations, guaranteed by the parent company.

Zai Lab reported a 3% decline in net product revenue for Q2 2026, driven by ZEJULA and VYVGART, while R&D expenses increased significantly due to licensing fees, though pipeline advancements and a new schizophrenia drug launch offer future potential.

Zai Lab Limited announced its first quarter 2026 financial results, reporting a 6% decrease in total revenues to $99.6 million, primarily driven by lower product sales.

Zai Lab reports a 13% increase in Q3 2025 net product revenue, driven by NUZYRA and XACDURO sales, alongside significant clinical advancements and a reduced net loss.

Zai Lab Limited reported a significant reduction in net loss and increased product revenue for Q2 2025, driven by strong sales of VYVGART and new launches, alongside positive clinical trial advancements.

Zai Lab's Q1 2025 revenue increased by 21% year-over-year, driven by strong sales of NUZYRA, VYVGART, and ZEJULA, while the company continues to advance its pipeline.

Zai Lab's third quarter results show a 47% increase in product revenue compared to the same period last year, driven by strong sales of VYVGART, ZEJULA, and NUZYRA.

Zai Lab Limited reported a 15% increase in total revenue to $460.2 million and a 32% decrease in net loss to $175.5 million for 2025, driven by commercial product performance and pipeline advancements.

Zai Lab Limited's 2024 10-K filing reveals a year of revenue growth, pipeline advancement, and strategic collaborations, alongside ongoing financial losses and operational risks in China.

Zai Lab Limited's 10-K filing provides a detailed description of its share structure, including ordinary shares and American Depositary Shares (ADSs), and outlines regulatory compliance measures.

Yajing Chen, Chief Financial Officer of Zai Lab Ltd, reported multiple transactions in common stock on August 14, 2026.

Yajing Chen, Chief Financial Officer of Zai Lab Ltd, sold 619 shares of common stock on August 11, 2026 for $25.00 per share.

Zai Lab Ltd. Director Richard Gaynor acquired American Depositary Shares (ADSs) under a pre-arranged trading plan, indicating continued confidence in the company.

Zai Lab Ltd. reports on changes in beneficial ownership for Chairperson & CEO Du Ying, involving the acquisition and disposition of American Depositary Shares.

Zai Lab Ltd. reports changes in beneficial ownership for Chairperson & CEO Du Ying, including acquisition of shares upon RSU vesting and subsequent sale to cover taxes.

Zai Lab Ltd. reports Chief Legal Officer Titus F. Edmondson III's transactions involving the acquisition of American Depositary Shares upon RSU vesting and subsequent sale to cover taxes.

Zai Lab Limited has issued its proxy statement for the 2026 Annual General Meeting of Shareholders, detailing proposals for director re-elections, auditor appointments, and share mandates.

Zai Lab Limited has filed a definitive proxy statement with the Securities and Exchange Commission.

Zai Lab Limited is holding its 2025 Annual General Meeting of Shareholders on June 18, 2025, to vote on the re-election of directors, appointment of auditors, executive compensation, and mandates for share issuance and repurchase.

Zai Lab Limited has filed a definitive proxy statement with the U.S. Securities and Exchange Commission.

Zai Lab is holding its 2024 Annual General Meeting to vote on key proposals including director re-elections, auditor appointments, executive compensation, and a new equity incentive plan.

TCG Crossover Fund II and III, led by Chen Yu, have collectively reported a 5.3% beneficial ownership stake in Zai Lab Limited.

RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. have filed a joint Schedule 13G, reporting beneficial ownership of 5.2% of Zai Lab Limited's ordinary shares.

RTW Investments, LP and Roderick Wong, M.D. have disclosed a 6.3% beneficial ownership stake in Zai Lab Limited as of December 31, 2025.

Qiming Corporate GP IV and affiliated entities disclose a 4.4% beneficial ownership in Zai Lab Limited as of December 31, 2025.

Wellington Management Group LLP and its affiliates reported a 4.3% beneficial ownership stake in Zai Lab Ltd. common stock as of December 31, 2025.

FMR LLC and Abigail P. Johnson disclose a 3.9% beneficial ownership stake in Zai Lab Ltd. common stock as of December 31, 2025.